Zacks Research Has Positive Forecast for SRPT Q1 Earnings

Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) - Research analysts at Zacks Research increased their Q1 2025 EPS estimates for Sarepta Therapeutics in a research note issued to investors on Wednesday, November 27th. Zacks Research analyst S. Ganoria now forecasts that the biotechnology company will earn $1.98 per share for the quarter, up from their previous estimate of $1.80. The consensus estimate for Sarepta Therapeutics' current full-year earnings is $2.09 per share. Zacks Research also issued estimates for Sarepta Therapeutics' Q2 2026 earnings at $3.66 EPS and Q3 2026 earnings at $3.63 EPS.

Several other research firms also recently issued reports on SRPT. Raymond James restated an "outperform" rating and set a $150.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, October 10th. William Blair raised shares of Sarepta Therapeutics to a "strong-buy" rating in a research note on Friday, August 30th. Evercore ISI cut their target price on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an "outperform" rating on the stock in a research note on Thursday, November 7th. Barclays decreased their target price on Sarepta Therapeutics from $226.00 to $203.00 and set an "overweight" rating for the company in a research report on Thursday, August 8th. Finally, HC Wainwright assumed coverage on Sarepta Therapeutics in a research report on Monday, November 25th. They set a "sell" rating and a $80.00 price target on the stock. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, twenty have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $175.77.

Sarepta Therapeutics Price Performance

NASDAQ:SRPT traded down $5.72 during mid-day trading on Monday, reaching $127.62. 745,170 shares of the stock were exchanged, compared to its average volume of 1,244,104. Sarepta Therapeutics has a 1-year low of $83.97 and a 1-year high of $173.25. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The firm has a market capitalization of $12.19 billion, a PE ratio of 101.42 and a beta of 0.81. The business has a fifty day moving average price of $122.50 and a 200 day moving average price of $131.48.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of SRPT. Innealta Capital LLC acquired a new position in shares of Sarepta Therapeutics during the second quarter valued at about $31,000. Sunbelt Securities Inc. raised its holdings in Sarepta Therapeutics by 446.2% in the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company's stock valued at $35,000 after acquiring an additional 232 shares in the last quarter. Huntington National Bank lifted its position in shares of Sarepta Therapeutics by 150.9% in the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company's stock worth $36,000 after acquiring an additional 175 shares during the period. Nkcfo LLC acquired a new stake in shares of Sarepta Therapeutics during the 2nd quarter worth approximately $43,000. Finally, Riggs Asset Managment Co. Inc. increased its position in shares of Sarepta Therapeutics by 33.3% during the second quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company's stock valued at $47,000 after purchasing an additional 75 shares during the period. Institutional investors and hedge funds own 86.68% of the company's stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.